Kristensen FP, Christensen DH, Callaghan BC, et al. - Researchers investigated if the risk of diabetic polyneuropathy (DPN) is impacted by statin therapy. For this purpose, they selected all Danish patients with incident type 2 diabetes during 2002–2016. New users were those who started taking statins between 180 days prior to and 180 days following their first diabetes record; prevalent users were defined as those who started statins prior to that time. In this study, 59,255 (23%) new users, 75,528 (29%) prevalent users, and 124,842 (48%) nonusers were analyzed. A median follow-up of 6.2 years was performed. Based on the findings, it was concluded that an increase or mitigation of the risk of DPN in correlation with statin therapy was unlikely in patients suffering from type 2 diabetes, although that could not exclude a small acute risk of harm. There was a slightly increased DPN risk during the first year among new users, but it was gone following >2 years of follow-up.